secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-006327
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen rebrands as Kyntra Bio; new ticker KYNB effective Jan 8; pipeline milestones detailed
--------------------------------------------------------------------------------

- Name changed to Kyntra Bio, Inc. via Certificate of Amendment effective 4:30pm ET Jan 7, 2026.
- Common stock to trade under symbol KYNB on Nasdaq at market open Jan 8, 2026; CUSIP unchanged.
- CEO cites sale of FibroGen China, payoff of term loan, and cash runway extended into 2028.
- FG-3246 Phase 2 monotherapy interim results expected H2 2026; topline Phase 1b/2 combo at ASCO GU Q1 2026.
- Roxadustat granted FDA Orphan Drug Designation for MDS; pivotal Phase 3 protocol submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/fgen-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer